Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139067 | 0.85 | SMN1; SMN2 (0.43) | KIF11SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL16715243 | 0.83 | SMN1; SMN2 (0.39) | KIF11SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL4804197 | 0.82 | KIF11 (0.49) | KIF11 | |
| SCHEMBL9999946 | 0.80 | KIF11 (0.47) | KIF11 | |
| SCHEMBL12390525 | 0.80 | KIF11 (0.47) | KIF11 | |
| SCHEMBL357884 | 0.77 | KIF11 (0.45) | KIF11ALDH1A1 | |
| SCHEMBL18704722 | 0.77 | KIF11 (0.45) | KIF11SMN1; SMN2 | |
| SCHEMBL23299724 | 0.77 | KIF11 (0.47) | KIF11HPGDL3MBTL1 | |
| SCHEMBL10744128 | 0.76 | KIF11 (0.54) | KIF11 | |
| SCHEMBL19903787 | 0.74 | HPGD (0.52) | KIF11HPGDL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3085373-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1988896-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100634-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | KIF11 2020/4885SMN1; SMN2 4620/4885CA12 2125/4885 |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | KIF11 2020/4885SMN1; SMN2 4620/4885CA12 2125/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | KIF11 2020/4885SMN1; SMN2 4620/4885CA12 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.